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Abstract
Excessive alcohol intake is associated with 5.9% of global deaths. However, this figure is especially acute in men such that
7.6% of deaths can be attributed to alcohol intake. Previous studies identified a significant interaction between genotypes of
the galanin (GAL) gene with anxiety and alcohol abuse in different male populations but were unable to define a mechanism.
To address these issues the current study analysed the human UK Biobank cohort and identified a significant interaction (n=
115,865; p= 0.0007) between allelic variation (GG or CA genotypes) in the highly conserved human GAL5.1 enhancer,
alcohol intake (AUDIT questionnaire scores) and anxiety in men. Critically, disruption of GAL5.1 in mice using CRISPR
genome editing significantly reduced GAL expression in the amygdala and hypothalamus whilst producing a corresponding
reduction in ethanol intake in KO mice. Intriguingly, we also found the evidence of reduced anxiety-like behaviour in male
GAL5.1KO animals mirroring that seen in humans from our UK Biobank studies. Using bioinformatic analysis and co-
transfection studies we further identified the EGR1 transcription factor, that is co-expressed with GAL in amygdala and
hypothalamus, as being important in the protein kinase C (PKC) supported activity of the GG genotype of GAL5.1 but less so
in the CA genotype. Our unique study uses a novel combination of human association analysis, CRISPR genome editing in
mice, animal behavioural analysis and cell culture studies to identify a highly conserved regulatory mechanism linking anxiety
and alcohol intake that might contribute to increased susceptibility to anxiety and alcohol abuse in men.
Introduction
The relationship between alcohol abuse and anxiety has
been extensively explored [1] but the genomic mechanisms
linking them remain poorly understood. Previous studies
have shown that the galanin neuropeptide (encoded by the
GAL gene) influences alcohol intake [2, 3] and anxiety-like
behaviour [4]. Moreover, genetic analyses of different
genotypes within the GAL locus succeeded in identifying an
association with excess alcohol intake that was influenced
by sex and anxiety [5]. Unfortunately, these studies were
unable to define a mechanism to explain these interactions
as the GAL coding region lacks non-synonymous poly-
morphisms [5]. Although there is a possibility that mis-
regulation of GAL may affect alcohol intake and anxiety,
little is known of the genomic mechanisms that modulate
the expression of the GAL gene in the brain.
Based on the hypothesis that regions of the genome
essential to species fitness are conserved through evolution
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[6, 7], we undertook a comparative genomic analysis of
the genome surrounding the human GAL locus and suc-
ceeded in identifying a highly conserved enhancer
sequence (hGAL5.1) 42 kilobases (kb) from the GAL gene
transcriptional start site [8]. We demonstrated that
hGAL5.1 was active in galanin-expressing cells of the
hypothalamus including the periventricular (PVN) and
dorsomedial hypothalamus (DMH) [8]. We also found that
GAL5.1 contained two polymorphisms in perfect linkage
disequilibrium (LD; rs2513280 (C/G) and rs2513281 (A/
G)) that produced two different genotypes (GG and CA)
within the human population and reported that the major
GG genotype was significantly more active in primary
hypothalamic neurones than the minor CA genotype [8].
Analysis of these genotypes in human populations detec-
ted an association of the GG genotype and volume of
alcohol intake in women in a small US cohort (n= 138)
[9]. However, a second UK (n= 2731) and US cohort
(n= 4064) based study, although initially identifying an
association to increased frequency of binge drinking in
teenagers, failed to reach significance after correction for
multiple comparison [10]. Because of the comparatively
small size of these studies we interrogated a much larger
human cohort (UK biobank) to better determine the
association of specific allelic variants in GAL5.1 with
levels of alcohol intake and anxiety in UK men and
women. In addition, we used CRISPR genome editing to
disrupt GAL5.1 in mice and examined the effects on the
expression of flanking genes in areas of the brain including
the hypothalamus and the amygdala to functionally link
GAL5.1 activity to the expression of five flanking genes
including Gal. Our study also characterises the effects of
GAL5.1 disruption on ethanol consumption and anxiety-
like behaviour in mice. In addition, a combination of
bioinformatics (DNAseI hypersensitivity) and co-
transfection studies identified a transcription factor-DNA
interaction underpinning GAL5.1 function and its
response to signal transduction cues. This study highlights
a novel mechanistic link between ethanol consumption and
anxiety centred on the GAL5.1 enhancer that may con-
tribute to the development of alcohol abuse and anxiety in
men [11, 12].
Methods
Genetic association study in humans
Genetic association analyses with alcohol consumption
(units consumed per week) were performed using BGE-
NIE, version 1 [13] with alcohol consumption as the out-
come variable and age, sex, genotyping array and the first
20 genetic principal components as covariates. We then
split the sample into males and females and repeated the
association analysis, removing sex as a covariate. The
mean alcohol intake in the total population was 15.3 units
per week (SD= 16.0). The mean age of the population was
56.2 years (SD= 8.0). Men self-reported higher weekly
alcohol intake compared with women (20.7 units (SD=
18.4) versus 10.5 units (SD= 11.5). Analysis of the
association of alcohol intake and allelic variation at the
rs2513280 locus was undertaken on a population of
345,140 individuals (UK Biobank (UKB); 183,921
females and 161,219 males all unrelated White British
individuals).
To analyse the interaction effect of rs2513280 and
anxiety on alcohol use behaviour in humans, we also ana-
lysed a subset of the UK Biobank [14] who had responded
to a mental health questionnaire (MHQ) the results of which
were made available to researchers in August 2017 [15].
The MHQ had information on anxiety and in this follow-up
alcohol use was ascertained using the AUDIT [16]; a 10-
item questionnaire used to measure both alcohol con-
sumption and problematic drinking. AUDIT total scores
range from 0 to 40 and the derivation of this measure in the
UKB has been described previously in greater detail [17].
For both sets of alcohol analyses, former and never drinkers
were removed.
Anxiety was ascertained by asking participants “Over the
last 2 weeks, how often have you been bothered by any of
the following problems? Feeling nervous, anxious or on
edge” [UKB data field 20506]. Anxiety was then dichot-
omised by comparing those answering, ‘Not at all’ to
individuals endorsing ‘Several days’, ‘More than half the
days’ or ‘Every day’. After filtering the MHQ subset of
individuals on those who were White, British and unrelated
with and non-missing data there remained 115,865 indivi-
duals available for analysis. Linear regression models
implemented in R were used to test the association between
AUDIT score and rs2513280 genotype and the interaction
effects of anxiety and sex. With AUDIT score as the out-
come variable we fitted rs2513280, sex and anxiety as main
effects and then a three-way interaction term of sex*-
anxiety*rs2513280. We also used twenty principal com-
ponents as covariates to adjust for potential population
stratification in the UK Biobank sample. rs2513280 geno-
type was modelled as a continuous variable (coded 0,1,2
corresponding to the number of C alleles carried).
Generation of gRNA molecules by a novel annealed
oligo template (AOT) method
Single guide RNA (sgRNA) molecules were designed to
disrupt the GAL5.1 enhancer using the optimised CRISPR
design tool (http://CRISPR.mit.edu/). sgRNA template was
produced by annealing oligonucleotides to produce two

different DNA templates as previously described [18] that
included a T7 polymerase binding site and predicted guide
sequence target sites spanning the most conserved central
region of the mGAL5.1 enhancer (5′sgRNA; CTC CCT
GGA GCA ATA TGA AG and 3′sgRNA; CCC GCT TTC
ATG GCT CCC AA). These oligonucleotides were
annealed and amplified using PCR to produce a 122 bp
double strand sgRNA template. A total of 100 ng of this
template was used to produce sgRNA using a mMESSAGE
mMACHINE T7 in vitro transcription kit (Ambion)
described in the manufacturer’s instructions and purified
using a Megaclear kit (Ambion) with modifications as
previously described [19].
Production of genome edited mice
sgRNA molecules were microinjected at a concentration
10 ng/µl each into the cytoplasm of 1-cell C57BL/6
embryos (Harlan, UK) as described [19] together with 10
ng/µl CAS9 mRNA (Life Technologies). Two-cell embryos
were introduced into host CD1 mothers using oviduct
transfer as previously described [20] and correctly targeted
offspring were determined by PCR of earclip DNA using
the following flanking primers (mGAL5for; AGTTAGGG
CGCACACATCAA, mGAL5rev; CCGTGACTAACG GC
TAATGC). These PCR products were purified and
sequenced. Sequencing data was then analysed using
the Blat tool (https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC187518/ “BLAST-like alignment tool”) of the UCSC
browser to compare the sequence of the PCR product
against that of the mouse genome (Fig. 1f, g).
In situ hybridisation
Radioactive in situ hybridisation was carried out on 10 μm
brain sections derived from wild-type mice using radi-
olabelled Gal or Early Growth Response gene 1 (EGR1 or
Zif268)) antisense RNA probes as previously described [21].
Quantitative reverse transcriptase-PCR
Brain tissues were dissected as described (hippocampus
and cortex [22]; hypothalamus [23] and Amygdala [24]
and Fig. S1) out of the whole brain and snap frozen on dry
ice. Total RNA was extracted using the isolate II RNA
minikit (Bioline). Quantitative reverse transcriptase-PCR
(QrtPCR) to determine mRNA expression levels of genes
flanking mGAL5.1 (Low-density lipoprotein receptor-
related protein 5 (Lrp5), Protein Phosphatase 6 Reg-
ulatory Subunit 3 (Ppp6r3), Gal, Tesmin (Mlt5) and car-
nitine palmitoyltransferase 1A (Cpt1a) was undertaken
using gene specific primers (Table S1) on derived cDNA
using mouse QrtPCR primers as previously described
[25, 26] using a Roche Light Cycler 480 with Roche
SYBR green. All QrtPCR analyses were normalised using
mouse primers specific to the Non-POU Domain Con-
taining Octamer Binding protein (Nono) housekeeping
gene that gave the most stable expression in all neuronal
tissues analysed compared with βactin, hypoxanthine-
guanine phosphoribosyltransferase or glyceraldehyde-3-
phosphate dehydrogenase genes.
Animal studies
All animal studies were performed in accordance with UK
Home Office guidelines. All mice used were sex and age
matched (12–18 weeks) littermates except where indicated.
Phenotypic analysis of the morphology, general health,
motility, behaviour and breeding success of these animals
was also carried out. All animals were assigned random
numbers after genotyping so that none of the operators
knew the genotypes of the animals prior to testing.
Alcohol preference studies
Preference for ethanol was tested by allowing animals free
access to a choice of 10% v/v ethanol or pure water intake
using a two-bottle choice protocol as described previously
[27]. Mice were housed in TSE home cage systems (TSE-
systems) that record liquid intake automatically. Initially
mice were group housed (~4/cage) and habituated for
5 days to allow for adaptation to the monitored bottles. The
mice were subsequently singly housed and habituated for a
further 5 days prior to introduction of a second bottle
Fig. 1 GAL5.1 is active in Gal expressing cells of the hypothlamus
and amygdala and can be rapidly and accurately disrupted using
CRISPR genome editing. Dark field images of 10 µm sections
through (a) the hypothalamic region and (c) the amygdala region of
wild-type mouse probed with S [36] labelled Gal antisense RNA.
Vibratome sections through (b) the hypothalamic and (d) the amygdala
regions of mice transgenic for the human GAL5.1-LacZ reporter
construct (hGAL5.1-LacZ) demonstrating LacZ expression in cells of
the periventricular (PVN) Dorsomedial (DMH) and arcuate (ARC)
nuclei (V3, 3rd ventricle) of the hypothalamus (a, b) and the (MeA)
medial amygdaloid nucleus of the amygdala (c, d). e Comparative
genomic analysis of sequence flanking the human GAL locus
demonstrating the position (numbered black scale bar at top), distance
(blue arrows) and depth of conservation (green peaks) of the human
GAL5.1 locus (red box) relative to the GAL gene (blue box). f, g DNA
sequencing data derived from PCR products of earclip DNA derived
from a homozygote GAL5.1KO mouse (thick black bar labelled
GAL5.1KO58) and blasted against the mouse genome (UCSC brow-
ser). The sequence disruption produced by introduction of CAS9/
sgRNA is displayed relative to the PAM sequence (green box) of each
sgRNA demonstrates the accuracy of (f) 5sgRNA and (g) 3sgRNA
relative to the missing regions of the genome (thin black lines and
chevrons). Electrophoresis gels demonstrating the difference in PCR
product sizes are published elsewhere [31].
containing the ethanol solution. Intake of both water and
10% ethanol solution were monitored at 30 min intervals
over the course of the trial and recorded by TSE Pheno-
Master Software (TSE-systems). Bottles were regularly
swapped to reduce positional effects on consumption. A
taste preference test to identify differences in sweet and
bitter taste preferences between wild type and GAL5.1KO
animals was performed by offering animals a choice of
water, water and saccharine (2 mM) or water and quinine
(0.3 mM; Supplementary Data 5) [28].
Open field test (OFT)
The OFT consisted of a square 30 cm (30 cm high) PVC open
field arena positioned on a white base with overhead lighting
applying 100 lx at the base [29]. Animals were transported
individually to the testing room, habituated (30mins) and
released into the corner of the arena. Ambulatory activity was
recorded in the open field for 300 s using an overhead video
camera and the ANY-maze tracking software (Stoelting
Europe). The software was used to define two zones in the
open field at ~35 cm2 centre zone and 30 cm2 peripheral zone.
Distance travelled, mean speed, Peripheral zone and no.
centre entries, were determined by the software.
Elevated zero maze (EZM)
The EZM consists of an annular dark grey platform (60 cm
in diameter) constructed of opaque Perspex divided into
four equal quadrants. Two opposite quadrants were “open”;
the remaining two “closed” quadrants were surrounded by
16 cm high dark, opaque black walls. Quadrant lanes were
5 cm in width. Overhead lighting applying 100 lx at the
level of the maze. The movement of animals was tracked
using a camera and ANY-maze tracking software. Distance
travelled, average speed, number of crossings between light/
dark zones and freezing episodes, freezing time and freez-
ing latency were recorded.
Novel suppressed feeding test (NSFT)
The NSFT assesses levels of anxiety by measuring the
latency of a fasted animal to approach and eat a familiar
food in an unfamiliar environment. The NSFT resembles
the OFT except that animals are fasted for 16 h before the
test and the animal is then placed in the open field
apparatus with a pellet of food fixed to a disc of filter
paper and placed in the centre of the cage. The latency
period between placing the animal in the test and first bite
of the food pellet was recorded. The numbers of lines
crossing and the speed and distance covered by the animal
during the test was also recorded.
Marble burying test (MBT)
The MBT consisted of a “Eurostandard type iv s” (Techi-
plast) cage (480 × 375 × 210 mm) cage with 5 cm depth of
wood chip bedding onto which 20 evenly spaced marbles
were placed. Animals were then placed in the cage and the
numbers of marbles buried after 30 min were recorded.
GAL5.1 deletion and expression constructs
Primers were designed that flanked the conserved putative
EGR1 binding site within the GAL5.1 enhancer (ARM212-
D2F; ATA GAT TTC AGA AAA GAA AGC TT, ARM213-
D2R; TAA AAT GAC TGG CAT TAG AGC TC-3′). These
were used in a PCR reaction with Q5 Hi-Fidelity polymerase
(NEB, USA) in combination with the pLuc-GAL5.1 reporter
construct previously described [8] as template to produce
pLuc-GALΔEGR. The PCR product was ligated with T4
ligase prior to transformation into competent cells (Stratagene).
The plasmid was sequenced to validate the removal of the
putative EGR1 binding site. Expression constructs (pcDNA-
EGR1 and pcDNA-PKCε) were obtained from Addgene.
Cell culture and transfection studies
SH-SY5Y cells (94030304, ECAC) were cultured in Dul-
becco’s Modified Eagle Medium (DMEM; Gibco,) containing
low Glucose (5.5 mM), L-Glutamine (4 mM), and Sodium
Pyruvate (1 mM). Medium was previously supplemented with
10% (v/v) heat-inactivated Foetal Bovine Serum (FBS;
Gibco) and 1% (v/v) Penicillin–Streptomycin (Pen-Strep;
Gibco, UK). Cells were transfected with luciferase reporter
plasmids DNA described above using jetPRIME as per the
manufacturer’s instruction (Polyplus Illkirch). Assays were
normalised by co-tranfected with renilla luciferase plasmid
pGL4.74 (Promega) or by assaying total protein in extract.
After transfection, cells were treated with phorbol 12-myr-
istate 13-acetate (PMA; 100 nM in DMSO) or DMSO or PKC
antagonist (GF10930X; Tocris) for 24 h following which cells
were lysed for dual luciferase analysis as per the manu-
facturer’s instructions (Promega UK).
Data analysis
From in vivo studies we calculated that a minimum of 6–12
animals per group would enable detection of a 25% dif-
ference between different parameters (ethanol intake,
anxiety-like behaviour) with 80% power using one-way
analysis of variance (ANOVA) and/or general linear
modelling. Statistical significance of data sets was analysed
using either one-way ANOVA analysis with Bonferroni
post hoc tests or using two tailed unpaired parametric
Student’s t test as indicated using GraphPad PRISM ver-
sion 5.02 (GraphPad Software, La Jolla, CA, USA).
Results
The G allele of rs2513280 associates with increased
alcohol consumption in men when stratified against
anxiety
In order to test the validity of two previous association
analyses [9, 10], we investigated whether there was an
association between allelic variants of the GAL5.1
enhancer and increased alcohol intake in a much larger
cohort comprising 345,140 individuals (UK Biobank;
183,921 females and 161,219 males). In the total sample a
marginal association between the G allele of rs2513280 (a
proxy for both loci in perfect LD) and increased weekly
alcohol intake in women was identified (b= 0.008, s.e.=
0.004, p= 0.0463). When analysing males and females
separately, the association between male alcohol intake
and rs2513280 became non-significant (b= 0.004, s.e.=
0.006, p= 0.478); however, in females the association
was stronger and remained significant (b= 0.012, s.e.=
0.006, p= 0.037).
Because of the known link between anxiety and alcohol
abuse in men [30] we further investigated the interaction of
these variables with respect to rs2513280 using a subset of
the UK Biobank that also contained information relating to
anxiety [15]. DNA was derived from blood and there were
64,465 females and 51,539 males in the anxiety cohort.
There was an effect of male sex on AUDIT score with
males having significantly higher AUDIT scores than
females (Table 1, b= 0.34, SE= 0.005, p < 2 × 10−16).
Individuals with higher levels of self-reported anxiety also
had significantly higher AUDIT scores although there was
no main effect of the rs2513280 polymorphism (Table 1).
No significant interactions were detected between sex and
rs2153280 or anxiety and rs2513280 (Table 1). However,
anxious males reported significantly higher AUDIT scores
(p= 0.0007) if they carried the major allele at the
rs2153280 locus (Table 1 and Fig. S2A). Comparisons of
analyses carried out using AUDIT-T, AUDIT-C, and
AUDIT-P are also shown in for comparison (Fig. S2A.)
The GAL5.1 enhancer supports reporter gene
expression in specific regions of the brain including
the hypothalamus and amygdala
To further analyse the tissue-specific activity of hGAL5.1,
we cloned the human GAL5.1 enhancer next to a LacZ
reporter (hGAL5.1-LacZ) and used this construct to gen-
erate transgenic reporter mouse lines as previously descri-
bed [8]. Closer analysis of brain sections derived from these
mouse lines identified expression of the LacZ reporter in
cells of the PVN, DMH and arcuate nuclei (ARC; Fig. 1b)
of the hypothalamus as well as the medial nucleus of the
amygdala (MeA; Fig. 1c) that corresponded to the expres-
sion patterns of the endogenous wild-type mouse Gal gene
both at a tissue-specific (Fig. 1a, c) and cellular level [8].
Rapid and accurate disruption of mGAL5.1 in mice
was achieved using CRISPR/CAS9
To determine a functional role for GAL5.1 in vivo, we
chose two target sequences (5′sgRNA and 3′sgRNA) that
flanked the most highly conserved region of the
mouse GAL5.1 homologue (mGAL5.1; chr19:3440931-
3441185; Fig. 1e) and used our previously described AOT
method to produce sgRNAs that, when injected into
mouse embryos, would induce a disruptive 230 bp dele-
tion in mGAL5.1 [18]. We microinjected AOT derived
sgRNA and CAS9 mRNA into the cytoplasm of 90 1-cell
C57BL/6 mouse embryos. 90% of these embryos survived
and were oviduct transferred into host female CD1 mice to
generate a homozygous female and two heterozygous
male mice that contained identical deletions within
GAL5.1 following analysis by PCR and electrophoresis
(mGAL5.1KO; Fig. 1f, g) without any evidence of off-
target effects [31]. These mice were crossed onto wild-
type C57BL/6 mice to produce a colony of male and
female mGAL5.1KO heterozygote mice that were subse-
quently used to produce the age/sex and homozygote
wild-type and mGAL5.1KO littermate mice (determined
by PCR of earclip DNA from each animal prior to testing)
used in the current study. We also carried out an extensive
phenotypical analysis of GAL5.1KO animals based on
previous criteria [32] and found no significant observable
change in phenotypic or health status as a result of the
genetic modification and GAL5.1KO mice were healthy
and viable (see Figs. S3 and 4).
Table 1 Interactions between different variables after analysis of the
UK Biobank demonstrating a stronger than expected interaction (p=
0.0007) between anxiety, sex, allelic variation at the rs2513280 locus
and alcohol intake as measured by AUDIT score.
Variable Estimate SE P value
Sex (male) 0.34 0.005 <2 × 10−16
rs2513280 0.003 0.006 0.58
Anxiety 0.03 0.006 <3.7 × 10−6
Sex (male)*anxiety −0.005 0.01 0.60
Sex (male) *rs2513280 −0.01 0.009 0.12
Anxiety*rs2513280 −0.02 0.01 0.10
Sex (male)*anxiety*rs2513280 0.06 0.02 0.0007
Disruption of mGAL5.1 reduces expression of GAL in
amygdala, hypothalamus and hippocampus but
does not affect the expression of flanking genes in
hypothalamus
We compared the expression of the Gal gene in mRNA
derived from various regions of the brain in wild-type and
mGAL5.1KO mice. Expression of Gal mRNA was stron-
gest in the hypothalamus and the amygdala with some
evidence of Gal mRNA expression in hippocampus and
cortex (Fig. 2a, b). We observed that expression of Gal was
greatly reduced in all these tissues in mGAL5.1KO animals
(Fig. 2a, b) suggesting that mGAL5.1 is essential for a
significant proportion of Gal expression in these tissues.
We also analysed the influence of mGAL5.1 disruption
on the expression of Gal and four other genes flanking the
Gal locus in the hypothalamus namely Lrp5, Ppp6r3 (5′ of
mGAL5.1) Mtl5 and Cpt1a (3′of mGAL5.1) that are all
maintained in the same synteny block [33] in both humans
and mice spanning 536 kb in humans and 379 kb in mice
(Fig. 2c). Although we found strong down regulation of the
Gal gene we saw no significant change of expression in any
of the flanking genes suggesting a lack of requirement for
mGAL5.1 for expression of these genes in the hypothala-
mus (Fig. 2d) [34].
mGAL5.1KO animals exhibit a decreased preference
for ethanol
Because the GAL gene has been shown to control intake of
alcohol [2, 3] and that a polymorphism within the GAL5.1
enhancer was associated with increased alcohol intake in
women and in men who also reporting anxiety, we tested
the hypothesis that disruption of the mGAL5.1 enhancer
would reduce preference for ethanol in mice. We provided
ad libitum access to bottles containing either water or water
and 10% ethanol (both bottles sweetened with 0.05% sac-
charine) to singly housed mGAL5.1KO and WT male and
Fig. 2 GAL5.1 specifically regulates expression of the Gal gene in
the hypothalamus and amygdala but not flanking genes. a Bar
graph showing relative levels of Gal expression as measured by
QrtPCR in different brain areas (Hypo hypothalamus, Amyg amyg-
dala, Hipp hippocampus, Cort cortex) in wild-type (WT) and
mGAL5.1KO animals. b Scatter plots demonstrating QrtPCR analysis
of Gal mRNA expression in RNA derived from hypothalamus,
amygdala, hippocampus and cortex on total RNA derived from wild
type (WT) or GAL5.1 knockout (mGAL5.1KO) animals (**p < 0.01).
c Scale diagram (UCSC genome browser) representing genes
surrounding the mGAL5.1 enhancer (red box). Exons are displayed
as thick blue lines and introns by thin blue lines punctuated by
chevrons denoting the direction of transcription. Genomic coordinates
on mouse chromosome 19 are highlighted by black perpendicular
lines. d Scatter plots showing QrtPCR analysis of cDNA derived from
total hypothalamic RNA comparing mRNA expression of Lrp5,
Ppp6r3, Gal, Mtl5 and Cpt1A in wild-type and GAL5.1KO animals
normalised against the expression of the Nono gene (y-axis). (****p <
0.001, n.s. no significance).
female littermates mice and recorded intake for 10 days
(Fig. 3a, b). Both male and female mGAL5.1KO mice
consumed significantly less 10% ethanol than wild-type
animals when given the choice (Fig. 3a) and no significant
difference in intake was detected between sexes. On aver-
age, wild-type mice drank the equivalent of 3.7 g of pure
ethanol per kg per mouse per day whereas the GAL5.1KO
mice only drank 1.1 g (Fig. 3b). To rule out the possibility
that animals lacking the GAL5.1 enhancer had an altered
preference for sweet or bitter tastes, that would skew the
alcohol preference tests, we also carried out a taste pre-
ference test by offering wild type of GAL5.1KO animals a
choice of water or water sweetened with saccharine or made
bitter with quinine. We observed no evidence of altered
preferences for bitter or sweet tastes as a result of GAL5.1
disruption (Fig. S5).
mGAL5.1KO mice exhibit an increase in marble
burying and decreased latency to feed in the NSFT
Both the MBT and the NSFT have been widely used to
assess levels of anxiety-like behaviour in mice. Using the
MBT, we observed that both male and female
mGAL5.1KO animals buried significantly more marbles
within the 30-min period of the test than did their wild-
type littermates (Fig. S6) consistent with reduced anxiety.
In addition, we observed decreased latency in the time
taken for fasted mGAL5.1KO animals to take their first
bite of the food pellet within a novel environment
although this only achieved significance in the
mGAL5.1KO males (Fig. 3c). Intriguingly, both males
and female mGAL5.1KO mice demonstrated a significant
increase in both numbers of line crossing between the
peripheral zone and the centre zone (Fig. 3d) as well as the
distance travelled (Fig. 3e) within the arena during the
duration of the test.
Male mGAL5.1KO mice demonstrate reduced
anxiety-like behaviour in the OFT and the EZM tests
The OFT has been previously used as a test for anxiety-like
behaviour [35]. We first noticed a significant increase in the
amount of centre entries displayed by male mGAL5.1KO
mice compared with litter matched wild-type animals
(Fig. 4a). We also noted an increase in the proportion of the
distance moved by GAL5.1KO mice (Fig. 4b) as well as the
proportion of time spent within the centre zones (Fig. 4c).
No significant difference in these behaviours was observed
between female WT and mGAL5.1KO (fKO) mice exposed
to the OFT (Fig. 4a–c)
Fig. 3 GAL5.1 disruption decreases ethanol intake and modulates
anxiety-like behaviour in the novelty suppressed feeding test.
a Scatterplot demonstrating the percentage intake of 10% ethanol in
male and female mGAL5.1KO (KOe) and wild-type littermates (WTe)
compared with water alone in mGAL5.1KO mice (KOw) and wild-
type littermates (WTw; error bars, SEM, n= 12–14; ****p < 0.0001;
F= 30.83; d.f.= 3) over the 10 days of the experiment. b Scatterplot
demonstrating ethanol intake in mGAL5.1KO (KO) male and female
mice compared with wild-type littermates (WT) expressed as grams of
ethanol consumed per kilogram of mouse per day (error bars= SEM;
n= 12–14, ****p < 0.0001; t= 5.918; d.f.= 24). Scatter plots
demonstrating latency to feed (c F= 4.617; d.f.= 3), number of line
crossings (d F= 12.46; d.f.= 3) and distance travelled (e F= 5.965;
d.f.= 3) as analysed using the novelty suppressed feeding test (NSFT;
n= 7; error bars= SEM; n.s. not significant; *p= 0.05; **p < 0.01;
***p < 0.005; ****p < 0.0001).
The EZM measures the innate fear of small rodents for
open areas against the security of a closed area and is a
refinement of the elevated plus maze [36]. We observed that
male mice placed into the EZM displayed a significantly
greater percentage of their time within the open quadrants of
the maze (Fig. 4d). In addition, male mice travelled a greater
distance (Fig. 4e) at a marginally faster speed (Fig. 4f) whilst
crossing between the light and dark sides with greater fre-
quency (Fig. 4g). Much of the difference in overall speed and
distance between WT and KO males were attributable to the
observed reduction in freezing behaviour (frequency and
latency) displayed by male mGAL5.1KO animals compared
with wild-type animals (Fig. 4h, i). No significant difference
in anxiety-like behaviour was observed between wild-type
and GAL5.1KO female mice exposed to the EZM (Fig. 4d–i).
EGR1 interaction and modulation of the PKC
response varies with GAL5.1 genotype
To identify transcription factors that were involved in
modulating GAL5.1 activity we undertook a bioinformatic
analysis of the GAL5.1 enhancer using ENCODE data on
Fig. 4 mGAL5.1 deletion affects sex-specific aspects of anxiety-like
behaviour in the open field test and the elevated zero maze. Scatter
plots demonstrating increased number of centre entries (a F= 2.290,
d.f.=3), percentage distance moved in the centre zone (b F= 2.583,
d.f.= 3) and the percentage of time in the centre zone (c F= 2.176,
d.f.= 3) of male GAL5.1KO mice (mKO) compared with male wild-
type mice (mWT) using the open field test (OFT). Female GAL5.1KO
mice (fKO) and wild-type mice (fWT) demonstrated no significant
behavioural difference in the OFT (a–c). Scatter plots demonstrating
changes in the time spent in the open quadrants of the elevated zero
maze (EZM) (d F= 25.80, d.f.= 3), the distance travelled (e F=
3.605, d.f.= 3) the average speed (f F= 3.846, d.f.= 3), the numbers
of crossings between the light and dark zones (g F= 6.498, d.f.= 3),
the number of freezing episodes (h F= 6.088; d.f.= 3) and the time
until the first freezing event (i f= 16.48; d.f.= 3) by mKO and mWT
animals. Female GAL5.1KO mice (fKO) and wild-type mice (fWT)
demonstrated no significant behavioural difference (d–i) in the EZM.
(OFT, n= 10–12; EZM, n= 7; n.s. not significant; *p= 0.05; **p <
0.01; ***p < 0.005; ****p < 0.0001).
the UCSC browser (Fig. 5a). ENCODE identified highly
conserved regions of GAL5.1 that were sensitive to
DNAse1 digestion; a diagnostic of open, transcriptionally
active chromatin, in several different cell lines (Fig 5ai, b).
This analysis also highlighted the presence of a highly
conserved binding consensus of EGR transcription factors
that lay within the DNAseI hypersensitive region (Fig 5aii,
b) in a highly conserved region of GAL5.1 (Fig 5aiii, b).
Furthermore, EGR1 (AKA Zif268) is expressed in the PVN
(Fig. 5c) and is upregulated in the ARC in response to
anorexia stimulated melanocortin signalling [37]. We pro-
duced luciferase reporter constructs containing the GAL5.1
(GG) enhancer and a derivative of GAL5.1(GG) lacking the
conserved EGR binding site (pLuc-ΔEGR1). These were
transfected into a neuroblastoma cell line (SH-SY5Y) in the
presence of an empty expression vector (pcDNA3) or an
expression vector expressing the EGR1 protein (pcDNA3-
EGR1, Addgene). These experiments demonstrate that the
expression of EGR1 transcription factor in neuroblastoma
cells significantly increased GAL5.1 activity and that the
putative EGR1 binding site identified in GAL5.1 is critical
to this interaction (Fig. 5d). In order to confirm that the
effects of PMA on GAL5.1, as previously reported [8], were
PKC specific we tested the effects of different concentra-
tions of the PKC antagonist GF10930X on the PMA driven
upregulation of the GAL5.1(GG) genotype. We showed that
PMA induction was significantly reduced following co-
treatment with 1000 nM concentration of the PKC antago-
nist (Fig. 5e). Further analysis comparing the effects of
EGR1 expression on the GAL5.1(GG) and GAL5.1(CA)
genotype reporter constructs showed that, whilst the GG
genotype responded strongly to EGR1 expression in SH-
SY5Y cells, the CA genotype did not (Fig. 5f). In addition,
the PMA induced response of the CA genotype was blunted
in comparison with the GG genotype (Fig. 5f).
Discussion
Understanding the processes that modulate preference for
ethanol is particularly pressing in men where 7.6% of all
male deaths globally can be attributed to alcohol abuse
Fig. 5 EGR1 interaction and modulation of the PKC response
varies with GAL5.1 genotype. a UCSC browser output of 800 bp
surrounding the GAL5.1 enhancer showing regions of DNAseI
hypersensitivity (a (i) filled grey bars), conserved transcription factor
binding consensus sequences (a (ii) filled black boxes) and degree
(a (iii) blue peaks) and depth (a (iii) green lines) of sequence con-
servation. b UCSC output showing hypersensitivity sites (grey bars),
conserved EGR1 consensus sequences (black bars) and degrees of
conservation (Blue peaks). Multiz alignment of conserved consensus
sequences demonstrates degrees of conservation at the base pair level
where dots represent identical base pair to human. c In situ hybridi-
sation demonstrating the expression of Egr1 mRNA within the peri-
ventricular nucleus (PVN) of the mouse hypothalamus. d A scatterplot
demonstrating dual luciferase data derived from SH-SY5Y cells
transfected with different combinations of pcDNA3 (empty expression
vector), pLuc (empty reporter vector), pcDNA-EGR1 (Expression
vector expressing EGR1 transcription factor), pLuc-GAL5.1 (reporter
vector containing the GAL5.1 enhancer), pLuc-GalΔEGR (reporter
construct containing the GAL5.1 enhancer lacking the EGR binding
consensus shown in b (n= 5–6; F= 60.47; d.f.= 5). e A scatterplot
demonstrating the effects of different concentration of the PKC
antagonist GF10930X on the PMA stimulated activity of the pLuc-
GAL5.1 plasmid (GAL5.1) compared with the empty luciferase vector
(pLuc; n= 6, **p < 0.01; ***p < 0.005; F= 37.62; d.f.= 7). f A
scatterplot comparing the effects of co-transfection of an EGR1
expressing plasmid (pcDNA-EGR1) and/or PMA treatment on cells
co-transfected with a renilla luciferase expressing plasmid and a firefly
luciferase reporter constructs containing either the GG or CA geno-
types of the GAL5.1 enhancer (n= 4, n.s. no significance, ***p <
0.005; ****p < 0.001; F= 54.91; d.f.= 7).
through accidental death, cardiovascular disease, liver
damage and cancer [38]. Anxiety remains one of the most
frequent co-morbidities associated with excessive alcohol
intake [39] and identifying and understanding the genomic
mechanisms that link anxiety with excessive alcohol intake
will be an important component in understanding and
combating alcohol abuse [30]. A previous genotype analy-
sis of polymorphisms around the GAL gene locus in two
different populations (Finns and Plains Native Americans)
identified robust associations with alcohol intake and spe-
cific genotypes [5]. Intriguingly, this study also uncovered
evidence of a sex-specific role for anxiety in modulating
alcohol intake [5]. Unfortunately, the authors were unable to
identify a molecular mechanism that could account for their
findings. The current study explored the problem from the
initial standpoint of functionality. This was achieved by
analysing the effects of polymorphisms known to change
the activity of the highly conserved GAL5.1 enhancer
sequence found 42 kb from the GAL gene [8].
We began our analysis of a possible role for the GAL5.1
enhancer in alcohol intake by interrogating the UK Biobank
cohort to determine the validity of previous conflicting
smaller scale association studies [9, 10]. Our analysis sup-
ported observations by Nikolova et al. who reported an
association between the G allele of GAL5.1 and increased
alcohol intake in women [9] but not in men. Because
anxiety has been identified as an important variable influ-
encing alcohol intake in humans [1] and had also been
identified as being an important variable in modulating the
role of the GAL gene in alcohol intake [5], we carried out a
deeper analysis of the rs2513280 polymorphism UK bio-
bank by stratifying alcohol intake with anxiety. We were
intrigued to find a highly significant association (p=
0.0007) between reported anxiety and drinking behaviour in
men with the GG genotype that was not observed
in women.
To further explore the role of GAL5.1 in ethanol intake
we disrupted GAL5.1 in mice using CRISPR/CAS9 gen-
ome editing. Using QrtPCR of different brain regions of
GAL5.1 knockout mice, we found that disruption of
GAL5.1 had a significant impact on the expression of Gal
mRNA expression in hypothalamus, amygdala, hippo-
campus and cortex consistent with a requirement for
GAL5.1 for appropriate expression of Gal in these brain
regions. Moreover, analysis of gene expression of four other
flanking genes suggested that GAL5.1 is specific in its
modulation of the expression of the Gal gene in the hypo-
thalamus; although we are unable to rule out a possible role
for GAL5.1 in regulating the expression of these genes in
other tissues or the regulation of more remote genes.
However, the most striking outcome of the current study
was the observation that CRISPR/CAS9 disruption of
GAL5.1 significantly reduced preference for ethanol in both
male and female mice demonstrating a key role for GAL5.1
in ethanol preference and intake. These observations con-
trasted with previously observations of the effects of Gal
gene knockouts where reduction of ethanol intake primarily
observed in female mice [40]. These observed differences
might be partly explained by differences in the genetic
background of the GAL5.1KO (C57BL/6Harlan) and the
GAL gene deletion mice(129Ola/Hsd) [41]. There is also a
likelihood that, because disruption of the GAL5.1 enhancer
does not remove all expression of the Gal gene, many of the
sex-specific differences observed may also be explained by
the presence of residual sex-specific Gal gene expression in
different parts of the brain. A third likelihood could reflect
differences in the genetic loci targeted such that the Gal
gene and the GAL5.1 enhancer loci in mice are 26 kb apart
and represent regions of the genome subject to different
genetic and epigenetic influences. A fourth explanation, that
we cannot rule out, is the possibility that GAL5.1 also
controls the expression of other more remote genes
involved in ethanol intake whose interactions have yet to be
characterised.
Anxiety is one of the most frequently reported co-
morbidities of alcohol abuse [1, 39]. It is intriguing, there-
fore, that genetic analyses of different genotypes within the
GAL locus succeeded in identifying an association with
excess alcohol intake that was influenced by sex and anxiety
[5]. These observations are supported by our current ana-
lysis of the UK biobank human cohort that also identified a
significant association of a GAL5.1 enhancer polymorphism
with alcohol abuse when stratified against sex and anxiety.
We therefore asked whether our CRISPR/Cas9 knockout of
GAL5.1 altered anxiety-like behaviour in mice and whether
there was evidence of the apparent sexual dimorphisms
observed in previous studies [5] and in our UK Biobank
analysis. Our initial analysis of mGAL5.1KO mice using
the MBT demonstrated that removal of mGAL5.1 increased
the tendency of both male and female mice lacking GAL5.1
to bury marbles; an accepted diagnostic of anxiety-like
behaviour but also of obsessive compulsive disorder [42].
Interestingly, we also observed greatly increased numbers
of line crossing as well as more distance travelled by both
sexes of mGAL5.1 mice exposed the NSFT (AKA hypo-
neophagia) which suggests that GAL5.1 may play a role in
exploratory foraging behaviour [43]. However, we only
observed a decrease in feeding latency in the NSFT in males
lacking GAL5.1 which suggested the possibility that some
aspects of anxiety-like behaviour in mice are modulated by
GAL5.1 in a sex-specific manner. This hypothesis was
further reinforced by observations of the behaviours of
mGAL5.1KO mice exposed to the OFT who spent pro-
portionately more time in the centre of the OFT and moved
a further distance. Further support for this observation came
from the EZM whereby male mGAL5.1KO mice spent a
significantly larger proportion of their time in the open
quadrants of the EZM. Notably, these mice also displayed a
reduced number of freezing episodes providing further
evidence of a reduced fear response [44]. The observed sex-
specific reductions in anxiety demonstrated by
mGAL5.1KO mice in the NSFT, the OFT and the EZM are
consistent with the sexual dimorphism observed in our
stratified analysis of the UK biobank cohort and in previous
analysis of polymorphisms around the GAL gene [5]. It is
obvious that many more behavioural aspects of anxiety,
such as social interaction, stress and conditioned fear
response, need to be explored in these animals to better
comprehend the specific role played by GAL5.1 in anxiety-
related behaviour. Moreover, critics of the MBT and the
NSFT correctly point out that the results of these tests may
be skewed by an increase in compulsive behaviour and
appetite, respectively. Nevertheless, when the results of all
our behavioural tests are considered together, our study
suggests that the GAL5.1 enhancer plays an important role
in modulating significant sex-specific aspects of anxiety-
like behaviour and ethanol intake in both mice and humans.
Even though we have identified phenotypic differences
in the human population reflecting findings within our
mouse models, we are also aware that the changes in our
human cohort (2 bp change in hGAL5.1) are not strictly
equivalent to those induced in our mouse models (230 bp
deletion in mGAL5.1) and it would be expected that our
mouse deletion would produce a more extreme phenotype
than that seen in humans. Indeed, we recognise that only by
recreating both human the CA and GG genotypes in mice
and comparing their phenotypic effects might a truly
equivalent comparison be made. Nevertheless, our current
study represents an important step towards defining a better
understanding of the role of GAL5.1 in mammalian ethanol
intake and mood and defines a clearer path to identification
and analysis of other conserved enhancers involved in
modulating health and disease.
Closer analysis of the GAL5.1 sequence, using a com-
bination of bioinformatics and cell co-transfection studies,
suggested a functional interaction between the EGR1 tran-
scription factor and a highly conserved EGR binding site
within a highly conserved region of GAL5.1. EGR1 has a
high affinity for DNA and is known to be able to bind DNA
even when the DNA is methylated [45]. Nevertheless, the
literature describing the effects of ethanol on EGR1
expression and activity could be clearer. For example, it
was reported that EGR1 binding to DNA was reduced
following ethanol exposure [46]. In contrast, more recent
reports suggest that expression of EGR1 in the brain was
increased in animals exposed to ethanol [47, 48]. From a
mechanistic perspective it is possible that EGR1 acts as a
“pioneer factor” by being one of the first transcription fac-
tors that bind to the closed and methylated GAL5.1 locus
thus activating its tissue-specific activity. Interestingly, we
observed that the CA allele of GAL5.1 did not respond to
EGR1 expression and its PKC response was blunted. This is
an interesting observation as the EGR1 binding site is 100
bp from the closest of the SNPs within GAL5.1
(rs2513281). We propose that the EGR1 protein forms part
of a larger protein complex that interacts across the whole
GAL5.1 enhancer. It is therefore possible that EGR1
binding and GAL5.1 function is dependent on binding of
another, as yet unidentified, protein whose binding is
interrupted by one of the allelic variants of GAL5.1 thus
affecting EGR1 binding.
We also explored the possible interaction of PKC path-
ways in the activity of the GAL5.1 enhancer. Previous
analysis demonstrated that the non-specific PKC agonist
PMA increased the activity of GAL5.1 in primary hypo-
thalamic cells [8]. In the current study, we support these
previous studies by showing that antagonism of PKC
decreases the effects of PMA on GAL5.1 activity. We have
also expanded our analysis to show that the upregulation of
PKA pathways increase the effects of EGR1 expression on
the activity of the GG genotype of GAL5.1 but not in the
less active and protective CA genotype; an observation that
may allow us to design personalised therapies. Our best
candidate for the PKC isoform responsible for modulating
GAL5.1 activity, and to which we may target future drug
therapies, is PKC epsilon (PKCε) which is expressed in the
amygdala and PVN [49, 50]. Moreover, genetic deletion of
PKCε reduces ethanol intake [49] and anxiety-like beha-
viour in mice [50]. Future work will focus on determining
the possible relevance of this isoform in the activity of the
GAL5.1 enhancer and determining whether antagonism of
this, and other PKC isoforms, may reduce the activity of the
GG genotype to that of the protective CA genotype thus
opening the possibility of developing a novel personalised
anxiolytic therapy that reduces ethanol intake in men.
Conclusion
To the best of our knowledge, this is the first time that the
unique combination of techniques used in our study; com-
parative genomics, CRISPR/CAS9 genome editing and
behavioural analysis in mouse models, have been used to
establish a functional role for a tissue-specific enhancer
region in alcohol selection and mood in living animals. This
study is given even greater impact by our analysis of the UK
biobank cohort that demonstrates a link between increased
alcohol intake and anxiety in males paralleling that seen in
our CRISPR derived models. The current study also goes
some way to addressing the age-old question of whether
alcohol abuse causes anxiety (substance-induced anxiety
model), or whether alcohol use is caused by anxiety
(self-medication model), by providing supporting evidence
suggesting that a common mechanism contributes to both
behaviours (common-factor model) [1, 39].
Placing the current study within the wider context of
understanding the mechanistic basis of complex human
disease it is clear that an important step has been made in
bridging the gap between association analyses and
mechanism especially in light of the fact that the majority of
associated SNPs generated by GWAS are in the non-coding
genome [51]. Although histone markers (e.g. H3K4me1,
H3K27ac etc) and GWAS are currently the favoured tech-
niques used to identify candidate regulatory regions affected
by disease associated polymorphic variation on a genome
wide level the current study serves to emphasise that there is
also merit in the use of comparative genomics and func-
tional characterisation of the cell specific activity of putative
regulatory elements using CRISPR genome editing in cell
based and whole animal systems.
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